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Abstract
Zygomycetes are ﬁlamentous fungi with a worldwide distribution. This class of fungi encompasses two orders, i.e. the Mucorales and
the Entomophthorales. Members of the latter are associated with chronic cutaneous and subcutaneous infections that are limited to the
tropics and rarely disseminate to internal organs. The order Mucorales includes several species involved in rhinocerebral, pulmonary,
cutaneous, gastrointestinal and other less frequent infections in immunocompetent and immunocompromised individuals, and is charac-
terized by a tendency to disseminate. Portals of entry of zygomycetes are usually the lungs, skin, and gastrointestinal tract. A character-
istic property of zygomycetes is their tendency to invade blood vessels and to cause thrombosis—processes that result in subsequent
necrosis of involved tissues. Risk factors associated with zygomycosis include prolonged neutropenia and use of corticosteroids, solid
organ or haematopoietic stem cell transplantation, AIDS, poorly controlled diabetes mellitus, iron chelation with deferoxamine, burns,
wounds, malnutrition, extremes of age, and intravenous drug abuse. Recently, the widespread use of voriconazole for prophylaxis or
treatment of aspergillosis in patients with haematological malignancies has been linked with a rise in the numbers of cases of invasive
zygomycosis. As the symptoms, clinical signs and imaging ﬁndings of these infections are non-speciﬁc, a high index of suspicion is
required for timely diagnosis. Early diagnosis, correction of the underlying predisposing factors, aggressive surgical debridement of all
infected tissues and lengthy administration of antifungals are the only potentially curative options for this rare but emerging invasive fun-
gal infection.
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Introduction
Zygomycosis includes a variety of infections caused by the
Zygomycetes, a class of fungi with a ubiquitous and world-
wide distribution that is characterized by aseptate or pauci-
septate hyphae, unlike fungi with distinct septate hyphae, such
as Aspergillus spp. [1]. Zygomycetes are further subdivided
into two orders, the Mucorales and the Entomophthorales,
which produce distinct patterns of clinical manifestations.
More speciﬁcally, the order Entomophthorales (Conidiobolus
and Basiodobolus spp.) is associated with chronic cutaneous
and subcutaneous infections that are almost exclusively lim-
ited to the tropics and rarely disseminate to internal organs
[2]. For these infections, entomophthoramycosis is the
correct term. On the other hand, the order Mucorales
encompasses several genera (Rhizopus, Rhizomucor, Mucor,
Absidia, Apophysomyces, Cunninghamella, Saksenaea, etc.) that
are involved in rhinocerebral, pulmonary, cutaneous, gastroin-
testinal and other less common invasive fungal infections in
both immunocompetent and immunocompromised individuals
and have the tendency to disseminate. Mucormycosis is the
correct term for infections due to fungi of this order. The
term zygomycosis is used to describe any invasive infection
due to zygomycetes, although it is frequently used inter-
changeably with the term mucormycosis [3].
The portals of entry of zygomycetes are usually the respi-
ratory tract, the skin, and, less frequently, the gut. A charac-
teristic property of zygomycetes is their tendency to invade
blood vessels and cause thrombosis and necrosis of infected
tissues [1]. In typical cases, the infection progresses rapidly,
and unless the underlying risk factors are adequately and
promptly reversed, in association with wide surgical resection
of all necrotic areas and administration of amphotericin-based
antifungal therapy, death occurs [4]. As is the case with other
ﬁlamentous fungi, because of the low yield of blood cultures,
biopsy of the affected sites is the mainstay of diagnosis.
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Zygomycetes are unique among moulds in their ability to
infect human hosts with a broader range of risk factors than
other opportunistic moulds [3]. Thus, whereas infections
due to Aspergillus spp. are almost exclusively limited to
immunocompromised patients, many cases of zygomycosis
have been reported in individuals with no apparent underly-
ing immunosuppression.
Risk Factors
Risk factors associated with mucormycosis include prolonged
neutropenia and use of corticosteroids, haematological malig-
nancies (leukaemia, lymphoma, and multiple myeloma), aplas-
tic anaemia, myelodysplastic syndromes, solid organ or
haematopoietic stem cell transplantation, human immunodeﬁ-
ciency virus infection, diabetic and metabolic acidosis, iron
overload, deferoxamine use, burns, wounds, malnutrition,
extremes of age, i.e. prematurity or advanced age, and intra-
venous drug abuse [1–4]. Patients with solid tumours rarely
develop zygomycosis. Several of these factors are common
to immunocompromised individuals, whereas the association
with metabolic factors, i.e. metabolic and diabetic acidosis, is
quite characteristic of these emerging mycoses [5]. Recently,
the widespread use of voriconazole in treating aspergillosis
in patients with high-risk haematological malignancies or who
undergo haematopoietic stem cell transplantation has been
linked with a rise in cases of conﬁrmed zygomycosis in many
institutions worldwide. Physicians using voriconazole for pro-
phylaxis or treatment of aspergillosis in profoundly immuno-
compromised patients should be aware of the risk of
emergence of fungal pathogens that are intrinsically resistant
to this azole, such as zygomycetes [6–14].
In the past, the most common underlying risk factors
for invasive zygomycosis were poorly controlled diabetes
mellitus with associated ketoacidosis, open wounds, and
the use of deferoxamine to chelate iron or aluminium in
patients with iron overload or on dialysis [15]. More
importantly, a substantial number of cases were reported
in individuals with no clear predisposing factors. Recently, a
substantial increase in the numbers of cases of zygomycosis
has been noted in profoundly neutropenic patients with
high-risk leukaemia [16–27], in patients with myelodysplas-
tic syndromes [28–30], and in haematopoietic stem cell
[31–34] and solid organ transplant recipients [35–39].
Earthquakes and physical disasters, such as the 2004 tsu-
nami in Southeast Asia, have also been linked with
increases in the numbers of cases of cutaneous and subcu-
taneous zygomycosis due to traumatic inoculation of zygo-
mycetes into wounds [40–42].
Clinical Manifestations
On the basis of organ(s) involvement, ﬁve major forms of
invasive zygomycosis have been described, i.e. rhino-orbito-
cerebral, pulmonary, cutaneous, gastrointestinal, and
disseminated, although rarer cases of zygomycosis, such as
osteomyelitis and endocarditis, have been described. Roden
et al. reviewed all published reports of zygomycosis in the Eng-
lish literature since 1885. A total of 929 eligible cases were
reviewed. The mean age of patients was 38.8 years, and 65% of
the patients were male. The most common types of infection
were sinus (39%), pulmonary (24%), and cutaneous (19%). Dis-
semination developed in 23% of cases. The majority of patients
with malignancy (92 of 154, 60%) had pulmonary disease,
whereas the majority of patients with diabetes (222 of 337,
66%) had sinus disease [43]. Comparing primary sites of zygo-
mycosis, skin and gut is more frequently affected in children
compared to adults [44]. (In this Supplement, Roilides et al.
review cases in neonates and children.)
Rhinocerebral zygomycosis
Rhinocerebral zygomycosis is characterized by involvement
of the nose and paranasal sinuses, with frequent involvement
of the maxillary sinus, the orbit, the cavernous sinuses, and
the brain [20,26,30,45–48]. Although rhinocerebral zygo-
mycosis occurs in immunocompromised patients, it is more
common in patients with poorly controlled diabetes mellitus,
and can be the ﬁrst manifestation of the underlying metabolic
abnormality. In diabetics with ketoacidosis, chemotaxis,
adherence, spreading and oxidative burst of neutrophils are
severely impaired, and this is associated with failure to sup-
press the germination of fungal spores and with an inability
to kill proliferating hyphae [1]. Symptoms of zygomycosis of
the paranasal sinuses are neither pathognomonic nor speciﬁc
enough to distinguish zygomycetes from other pathogens
causing rhinosinusitis. Nasal obstruction or congestion with
noisy breathing, headache, odontalgia, maxillary pain and
hyposmia or anosmia may be seen. Necrotic eschars in the
nasal cavity, the turbinates or the palate, and necrotic facial
lesions, signify aggressive angio-invasive infections. Orbital
extension can lead to preseptal and orbital cellulitis, and is
associated with chemosis, eyelid oedema, proptosis, blurred
vision, double vision, worsening ophthalmoplegia, and, even-
tually, blindness. Intracranial extension is associated with a
depressed level of consciousness. Intracranial complications
include cavernous and, more rarely, sagittal sinus thrombosis,
and epidural or subdural abscess formation. Obtaining biopsy
specimens from necrotic lesions can help in making a rapid
histological diagnosis, which is of paramount importance for
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improving the clinical outcome. The mortality rate is extre-
mely high, and is associated with delayed diagnosis and
delayed institution of combined aggressive medical and surgi-
cal therapy.
Pulmonary zygomycosis
Pulmonary zygomycosis is more common in neutropenic
patients with underlying haematological malignancies or who
undergo haematopoietic stem cell transplantation. Its clinical
and radiological features are indistinguishable from those of
invasive pulmonary aspergillosis. Hence, patients present
with prolonged fever that is unresponsive to broad-spec-
trum antibiotics, non-productive cough, pleuritic chest pain,
and deteriorating dyspnoea. A friction rub may be heard on
auscultation. Haemoptysis is an ominous symptom, and can
be fatal, owing to erosion of a major lung vessel. The
absence of fever does not rule out any pulmonary invasive
fungal infection, especially in patients on corticosteroids. As
with pulmonary aspergillosis, high-resolution chest com-
puted tomography is the best method for determining the
extent of pulmonary involvement, and demonstrates evi-
dence of infection before chest radiographs. Halo and air-
crescent signs are encountered in cases of zygomycosis, as
in cases of pulmonary aspergillosis, and are non-speciﬁc.
Nodular, segmental, lobar or cavitary lesions can occur.
Chamilos et al. from the MD Anderson Cancer Center,
using logistic regression analysis, showed two clinical
parameters, i.e. concomitant sinusitis and voriconazole
prophylaxis, to be signiﬁcantly associated with pulmonary
zygomycosis as compared with aspergillosis in patients with
cancer, mostly haematological malignancies [49]. Among the
radiological parameters, the presence of multiple (‡10) nod-
ules and pleural effusion at the time of the initial chest
computed tomography scan were also independently associ-
ated with pulmonary zygomycosis as compared with asper-
gillosis [49]. Pulmonary zygomycosis can spread to other
organs if not promptly treated, and is associated with a
high case-fatality rate.
Cutaneous zygomycosis
The skin is a less common site of secondary involvement in
disseminated zygomycosis than with infections due to other
opportunistic moulds. Hence, in the review by Roden et al.,
haematogenous dissemination to the skin was rare [43]. On
the other hand, primary cutaneous zygomycosis is associated
with traumatic inoculation of the skin with zygomycetes in
immunocompromised patients, burn victims, and patients
with severe soft tissue trauma [16,17,35,50–61]. The clinical
symptoms and signs of erythema and induration are non-spe-
ciﬁc and indistinguishable from those of any cutaneous or
subcutaneous infection. Necrotic eschars are the diagnostic
hallmark, and should prompt an immediate biopsy of the
involved skin and subcutaneous fat. Zygomycetes are capable
of extending rapidly along tissue planes, especially in neu-
tropenic patients, and this property is associated with poor
clinical outcome. In the Roden et al. review, 44% of cutane-
ous infections were complicated by deep extension or dis-
semination [43].
Gastrointestinal zygomycosis
Gastrointestinal zygomycosis is uncommon and has been
mainly described in premature neonates, where it presents
as necrotizing enterocolitis with a swollen, erythematous
and tender abdomen. The disease is characterized by fungal
invasion into the gut mucosa, submucosa, and blood vessels.
Apart from prematurity, malnutrition, ingestion of contami-
nated food or of non-nutritional substances, severe under-
lying illness and immunosuppression are the most common
predisposing factors. Few cases have been described in
immunocompetent individuals. All parts of the gut can be
affected, although more commonly the disease presents
with an appendiceal, caecal or ileac mass or with gastric
perforation that may be associated with an upper, fre-
quently massive, gastrointestinal bleed [62–67]. Gastro-
intestinal perforation can lead to peritonitis with a high
mortality rate.
Disseminated zygomycosis
Disseminated zygomycosis is usually the result of dissemi-
nation from invasive pulmonary disease, although it may
originate from any of the primary sites of infection [68–
70]. Most cases are diagnosed by post-mortem examina-
tion of profoundly immunosuppressed patients. However,
several cases of disseminated zygomycosis have been
described in immunocompetent individuals after life-threat-
ening multiple injuries to various organs. The death rate
approaches 100%.
Rare forms of zygomycosis
A rare manifestation of zygomycosis is a primary renal form
that is usually conﬁrmed at autopsy [71,72] Although rare,
bilateral renal zygomycosis should be suspected in any immu-
nocompromised patient who presents with haematuria, ﬂank
pain, and unexplained anuric renal failure. Rare manifestations
of zygomycosis are involvement of the peritoneal cavity in
patients undergoing peritoneal dialysis [57,73–75], brain
involvement without rhino-orbital participation in leukaemic
patients and intravenous drug abusers [76], and endocarditis
in patients with artiﬁcial heart valves and rarely endocarditis
on native heart valves. [77–79].
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Conclusions
In conclusion, zygomycosis is becoming more frequent in
today’s era of highly active prophylaxis for Aspergillus spp.
Different sites can be affected; symptoms are non-speciﬁc,
and imaging ﬁndings are suggestive but not speciﬁc. Hence, a
high index of suspicion is required for the timely diagnosis of
this dreadful infection by physicians caring for immunocom-
promised individuals, but also caring for diabetics, sick pre-
mature neonates, debilitated elderly patients, those on
peritoneal dialysis or deferoxamine chelation, and trauma vic-
tims. Early diagnosis, correction of the underlying predispos-
ing factors, if possible, aggressive surgical debridement and
lengthy administration of amphotericin B are the only poten-
tially curative options for this rare but emerging invasive fun-
gal infection.
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